chimerism to 58% were documented. The patient received an initial donor lymphocyte infusion (with 10 8 T-cells/kg), and in 5 weeks improved both donor cell chimerism and bcr-abl molecular levels in the absence of any sign of GVHD. Upon a second donor leukocyte infusion (DLI), the patient developed acute GVHD grade II and in two consecutive tests his chimerism has been 100% donor and is in complete molecular remission. In this case, the patient was resistant to imatinib post-transplant, but it seems that treatment with imatinib post-transplant preceded a drop in donor cell chimerism as well as a cytogenetic relapse, which was successfully treated with DLI. Since, instead, it has been reported a beneficial effect of the association of imatinib and DLI, 6 we hypothesize that in patients partially responding/resistant to imatinib pretransplant, a possible T-cell suppressive effect of imatinib post-transplant could result in a reduced graft-versus leukemia, possibly facilitating a progression of the disease. The clinical case described by Chunduri et al highlights the importance of monitoring T-cell responses in vivo in patients treated with imatinib. The authors report the donor cell chimerism, minimal residual disease detected by BCR-ABL and clinical course in a patient who received allogeneic PBSCT from an HLA-matched sibling. 1 The patient had achieved only a minor cytogenetic response to imatinib prior to allograft and no improvement in donor cell chimerism or BCR-ABL transcript levels were observed with imatinib commenced 8 months posttransplant. Furthermore, within a month of cessation of imatinib relapse was observed at the cytogeneic level, and an associated significant reduction in donor cell chimerism was observed. Complete donor chimerism and molecular remission were detected only after DLI. It remains unclear whether imatinib does abrogate a graft-versus-leukaemia effect, but such observations support our findings, 2 and those of another group, 3 that imatinib inhibits T-cell responses in vitro. 
